Your SlideShare is downloading. ×
Neuropharmacology: Catecholamines
Neuropharmacology: Catecholamines
Neuropharmacology: Catecholamines
Neuropharmacology: Catecholamines
Neuropharmacology: Catecholamines
Neuropharmacology: Catecholamines
Neuropharmacology: Catecholamines
Neuropharmacology: Catecholamines
Neuropharmacology: Catecholamines
Neuropharmacology: Catecholamines
Neuropharmacology: Catecholamines
Neuropharmacology: Catecholamines
Neuropharmacology: Catecholamines
Neuropharmacology: Catecholamines
Neuropharmacology: Catecholamines
Neuropharmacology: Catecholamines
Neuropharmacology: Catecholamines
Neuropharmacology: Catecholamines
Neuropharmacology: Catecholamines
Neuropharmacology: Catecholamines
Neuropharmacology: Catecholamines
Neuropharmacology: Catecholamines
Neuropharmacology: Catecholamines
Neuropharmacology: Catecholamines
Neuropharmacology: Catecholamines
Neuropharmacology: Catecholamines
Neuropharmacology: Catecholamines
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Neuropharmacology: Catecholamines

872

Published on

Lecture 17 from a college level neuropharmacology course taught in the spring 2012 semester by Brian J. Piper, Ph.D. (psy391@gmail.com) at Willamette University.

Lecture 17 from a college level neuropharmacology course taught in the spring 2012 semester by Brian J. Piper, Ph.D. (psy391@gmail.com) at Willamette University.

Published in: Health & Medicine
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
872
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
54
Comments
0
Likes
1
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Neurochemistry of Catecholamines Brian J. Piper, Ph.D. Norepinephrine
  • 2. Goals• Biosynthesis• Receptors• Neuroanatomy• Diseases• Drugs – L-Dopa – Methylphenidate
  • 3. Definition• Catechol + amine (NH2) catechol• Members: – Dopamine – Norepinephrine (Noradrenaline) – Epinephrine (Nopepinephrine)
  • 4. Precursor• Tyrosine: amino acid found in many foods including cheese & dairy products
  • 5. Biosynthesis• Rate limiting (TH): controls production, found in axons
  • 6. Biosynthesis• L-DOPA: L-3,4-dihydroxyphenylalanine
  • 7. Parkinson’s Disease 1755-1824 • Progressive neurodegenerative disease • Described by James Parkinson in 1817 • Idiopathic (pesticides, genetics) • Prevalence: 3% of 65+ (500,000!) • Symptoms: resting tremor, pill rolling, slowness of movement • Tx: L-DOPA + peripheral AADC-I3 min: http://www.youtube.com/watch?v=ZHRT0uUo7Qs1 min: http://www.youtube.com/watch?v=_L_WF6gv5BI
  • 8. Thanks, home chemists!• Barry Kidston develops Parkinson’s after synthesizing MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)• Later cases were described as: – “Three of the four patients were hospitalized with 14 days to 6 weeks of first use of the drug. Examination in each revealed near total immobility, marked generalized increase in tone, a complete inability to speak intelligibly, marked diminution of blinking, fixed stare, constant drooling” – Stopping L-DOPA resulted in “complete immobility & rigidity, being only able to move his eyes” Langston et al. (1983). Science, 219, 979-980.
  • 9. MPTP= Parkinson’s model Immunocytochemistry for tyrosine hydroylase in rhesus monkeysParkinson’s Disease Normal Masilamoni et al. (2011). Brain, 134, 2057-2073.
  • 10. Dopamine Release• VMAT2: vesiciular monoamine transporter, packages DA into vesicle• Dopamine Transporter (DAT): found on cell membrane, recycles dopamine• Receptor Families: – D1: – D2:
  • 11. Dopamine Transmission• VMAT2: vesiciular monoamine transporter, packages DA into vesicle• DAT: Dopamine Transporter, found on cell membrane, recycles dopamine• Receptor Families: – D1: D1 & D5 – D2: D2 D3 D4
  • 12. Dopamine Neuroanatomy 1 Mesocortical• Label: Soma-Axon Location, Mesencephalon-Cortex• Important for Schizophrenia
  • 13. Dopamine Neuroanatomy 2 Mesolimbic• Limbic: amygdala, hippocampus, nucleus accumbens• Important for Drug-Abuse
  • 14. Dopamine Neuroanatomy 3 Nigrostriatal• Nigro: substantia nigra• Striatum: caudate and putamen• Important for movement
  • 15. Embryonic Transplants: An (Overly?)Optimistic Therapy
  • 16. Dopaminergic DrugsDrug MechanismResperine VMAT inhibitor (irreversible)AMPT Inhibits tyrosine hydroxylase Rauvolfia serpentina6-OHDA Destroys DA (& NE) neurons (snakeroot)SCH 23390 D1 antagonistHaloperidol D2 antagonistCocaine Inhibits reuptake of DA (& NE)methylphenidate Inhibits reuptake of DA (& NE) Tyrosine hydroylase staining following 6-OHDA lesion of left-fibers of nigro- striatal pathway.
  • 17. NorepinephrineSynthesis
  • 18. Adrenergic Receptors• α : α1 α2• β : β1 β2
  • 19. Functions of Norepinephrine
  • 20. Catecholamine InactivationNET (norepinephrine transporter): membraneboundMAO (monoamine oxidase): found in neurons &gliaCOMT (catechol-O-methyl-transferase):intracellular & extracellular
  • 21. ADHD Inattention• Symptoms present at school/work and home• 6+ symptoms that have persisted 6+ months and are inconsistent with developmental level – Often fails to give close attention or makes careless mistakes at school or at work. – Has difficulty sustaining attention in tasks or play. – Does not listen when spoken to directly. – Often does not follow through on instructions. – Has difficulty organizing activities. – Is easily distracted. – Is often forgetful in daily activities. 23
  • 22. ADHD: Hyperactive-Impulsive• Symptoms present at school/work and home• 6+ symptoms that have persisted 6+ months and are inconsistent with developmental level – Often fidgets with hands or feet, leaves seat when staying seated is expected, runs or climbs excessively – Often blurts answer before ? completed – Has difficulty waiting turn – Often interrupts others 24
  • 23. “Peculiar” Effects of Methylphenidate in Adolescents• Ritalin (Schedule II) is FDA approved for narcolepsy & ADHD• Pharmacological MRI was conducted in adolescent (PD35) and adult rats (PD 60+)Canese et al. (2009). Psychopharm, 203, 143-153.
  • 24. Summary• Synthesis (TH, AADC)• Breakdown (DAT/NET, VMAT, MAO, COMT)• Receptors – D1 D2 –αβ
  • 25. Is crystal methamphetamine the new crack? • Q) Is methamphetamine a national epidemic? • Q) Are there similarities between meth & crack? Dopamine Methamphetamine0-29:20http://www.justicetalking.org/ShowPage.aspx?ShowID=576

×